CD8A and neoplasm: Antibody-epitope conjugates (AECs) rely on the proteolytic release of epitopes near the tumor surface, presented by human leukocyte antigen (HLA) class I molecules, to ultimately target and activate virus-specific CD8+T cells to tumor cells.